Nucleocytoplasmic Proteomic Analysis Uncovers eRF1 and Nonsense Mediated Decay as Modifiers of ALS C9orf72 Toxicity
Juan Alberto OrtegaiD, Elizabeth L. DaleyiD, Sukhleen KouriD, Marisa Samani, Liana TelleziD, Haley S. SmithiD, Elizabeth HalliD, Y. Taylan EsenguliD, Yung‐Hsu TsaiiD, Tania F. GendroniD, Christopher J. DonnellyiD, Teepu SiddiqueiD, Jeffrey N. SavasiD, Udai Bhan PandeyiD, Evangelos KiskinisiD
Abstract
The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a hexanucleotide repeat expansion in C9orf72 (C9-HRE). While RNA and dipeptide repeats produced by the C9-HRE disrupt nucleocytoplasmic transport, the proteins that become redistributed remain unknown. Here, we utilized subcellular fractionation coupled with tandem mass spectrometry and identified 126 proteins, enriched for protein translation and RNA metabolism pathways, which collectively drive a shift towards a more cytosolic proteome in C9-HRE cells. Amongst these was eRF1, which regulates translation termination and nonsense-mediated decay (NMD). eRF1 accumulates within elaborate nuclear envelope invaginations in patient iPSC-neurons and postmortem tissue and mediates a protective shift from protein translation to NMD-dependent mRNA degradation. Overexpression of eRF1 and the NMD-driver UPF1 ameliorate C9-HRE toxicity in vivo. Our findings provide a resource for proteome-wide nucleocytoplasmic alterations across neurodegeneration-associated repeat expansion mutations and highlight eRF1 and NMD as therapeutic targets in C9orf72-associated ALS/FTD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 83
- FWCI
- 5.52
- Field percentile
- top 3%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Aberrant splicing exonizes C9ORF72 repeat expansion in ALS/FTD
Suzhou Yang, Denethi Wijegunawardana, … Junjie U. Guo·Nature NeurosciencePeer-reviewed·Aug 11, 2025
- High content live profiling reveals concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis.
Arun Pal, Benedikt Kretner, … Andreas Hermann·bioRxiv·Apr 15, 2020
- A cell-penetrant peptide blocking C9ORF72-repeat RNA nuclear export suppresses neurodegeneration
Lydia M. Castelli, Ya-Hui Lin, … Guillaume M. Hautbergue·Science Translational MedicinePeer-reviewed·Mar 1, 2023
- Safety and efficacy of C9ORF72-repeat RNA nuclear export inhibition in amyotrophic lateral sclerosis
Lydia M. Castelli, Luisa Cutillo, … Guillaume M. Hautbergue·Molecular NeurodegenerationPeer-reviewed·Aug 10, 2021
- CRISPR-Cas9 Screens In Human Cells And Primary Neurons Identify Modifiers Of C9orf72 Dipeptide Repeat Protein Toxicity
Nicholas J. Kramer, Michael Seamus Haney, … Aaron D. Gitler·Nature GeneticsPeer-reviewed·Feb 28, 2018
- Cell cycle dysregulation contributes to neurodegeneration in humanneurons from ALS/FTD-related C9orf72 repeat expansion carriers.
SK Imran Ali, Ling Lian, … Rodrigo Lopez-Gonzalez·bioRxiv·Jun 4, 2025